| | TP53 | CEN17 | AML1 |
|---|
CON (n = 20) | P < 10-10
| P < 10-10
| P < 10-10
|
ADI (n = 20) | P > 0.55 | P > 0.65 | P < 0.03 |
PRE (n = 14) | P > 0.40 | P > 0.75 | P > 0.95 |
POST (n = 10) | P < 10-7
| P < 10-7
| P < 10-7
|
- CON - samples of cancer free subjects; ADI - samples of patients with hematological malignancies obtained at diagnosis; PRE - samples of patients with hematological malignancies taken prior to alloSCT; POST - samples of patients with hematological malignancies taken following alloSCT; and n - Number of cases tested within each group for each locus. Each value (for each designated locus in each group of samples) is in respect to the levels of SD for SNRPN in the blood samples of the CON group (20 cases). The SD level for SNRPN in the ADI group was similar (P > 0.70) to that obtained in the CON group (see last bars in Figure 1A and 1B).
